Early detection is crucial. Survival rates are far higher when caught early.
Each day, the human body quietly sheds billions of dying cells, releasing fragments of DNA into the bloodstream — a kind of biological autobiography written in chemical ink. Researchers at UCLA have learned to read that script. Their test, MethylScan, deciphers methylation patterns in circulating DNA to detect multiple cancers and liver diseases from a single blood draw, catching roughly 63 percent of cancers with very few false alarms. It is an early chapter in a longer story about whether medicine can one day listen to the body's whispers before they become cries.
- Cancer's deadliest advantage is silence — most cases are found late, when survival odds have already narrowed, making early detection tools a matter of life and death.
- MethylScan cuts through the genetic noise of healthy circulating DNA using a filtering technique that isolates the more telling, methylated fragments shed by diseased cells.
- Tested across 1,061 patients with liver, lung, ovarian, and stomach cancers, the test achieved 98% specificity — meaning false alarms were rare — while detecting 80% of liver cancers specifically.
- Early-stage detection, the hardest and most critical target, remains a challenge, with sensitivity dropping to 55% for cancers caught before they spread.
- The study, published in the Proceedings of the National Academy of Sciences, positions MethylScan as a candidate for universal screening, but larger real-world trials must still prove it holds up outside controlled conditions.
Researchers at UCLA have developed a blood test called MethylScan that reads chemical signatures on DNA fragments circulating in the bloodstream, with early results suggesting it could detect multiple cancers and liver diseases before they advance. The science rests on a fundamental biological fact: tens of billions of cells die in the human body every day, releasing DNA that carries information about the health of every organ. The team focused on DNA methylation — chemical tags that control gene activity and shift in recognizable ways when cells become cancerous or diseased.
The central obstacle was noise. Most circulating DNA comes from healthy cells, which can obscure disease signals. The UCLA team addressed this by developing a filtering method that removes unmethylated fragments, leaving behind the more diagnostically useful material. Testing on 1,061 patients with various cancers and liver conditions, MethylScan detected 63 percent of cancers overall while maintaining 98 percent specificity — very few false positives. Liver cancer was the standout, with nearly 80 percent detection, and the test could also distinguish between different types of liver disease with roughly 85 percent accuracy.
Senior researcher Jasmine Zhou noted that the methylation patterns don't just flag disease — they help identify where in the body it originates, which is essential for directing follow-up imaging. The study, published April 6 in the Proceedings of the National Academy of Sciences, advances the vision of a single, affordable blood test capable of screening for many conditions at once. Larger clinical trials are still needed to confirm real-world performance, and the road from promising laboratory finding to standard clinical tool is never short — but the direction, for now, is hopeful.
Researchers at UCLA have developed a blood test that reads the chemical signatures written across DNA fragments floating in the bloodstream, and early results suggest it could become a practical tool for catching multiple cancers before they spread. The test, called MethylScan, works on a simple principle: every day, tens of billions of cells in the human body die and release their DNA into the blood. That genetic material carries information about what is happening in every organ, and scientists have learned to read it.
The key is something called DNA methylation—chemical tags that attach to DNA and control which genes are active or silent. These tags vary depending on tissue type, and they change in distinctive ways when cells become cancerous or diseased. Wenyuan Li, a pathology professor at UCLA, explained that methylation patterns function as a window into tissue health. The challenge was that most of the DNA circulating in blood comes from healthy cells, creating noise that obscures the signal. The UCLA team solved this by developing a filtering technique that strips away unmethylated DNA fragments before analysis, leaving behind the more informative genetic material.
To test how well the approach works, researchers analyzed blood samples from 1,061 people. Some had liver, lung, ovarian, or stomach cancers at various stages. Others had liver diseases including hepatitis B, hepatitis C, alcohol-related damage, and fatty liver disease. The results were encouraging but not perfect. Across all cancer types and stages, MethylScan detected about 63 percent of cases while maintaining a 98 percent specificity rate—meaning very few false alarms. For early-stage cancers specifically, the detection rate dropped to 55 percent. The test performed best on liver cancer, catching nearly 80 percent of cases while maintaining a specificity above 90 percent. It could also distinguish between different types of liver disease, correctly classifying about 85 percent of patients.
Jasmine Zhou, the senior researcher leading the work, emphasized why this matters. Survival rates are dramatically higher when cancer is caught at stage one rather than stage four. A blood test that could flag disease early enough for follow-up imaging or other diagnostics could change outcomes for thousands of people. The methylation patterns the test tracks also help pinpoint where in the body a problem originates, which is crucial because a positive blood result needs to lead to imaging of the right organ.
The study, published April 6 in the Proceedings of the National Academy of Sciences, represents a step toward what researchers call the dream of universal disease detection—a single blood test that screens for many conditions at once. But the work is not finished. Larger clinical trials are needed to confirm that MethylScan performs as well in real-world screening as it did in this controlled study. The test is simple and inexpensive, which means if it proves reliable at scale, it could become accessible to many people. For now, the promise is clear, but the path from laboratory finding to clinical tool remains uncertain.
Notable Quotes
Survival rates are far higher when cancers are caught before they spread. If you detect cancer at stage one, outcomes are dramatically better than at stage four.— Jasmine Zhou, UCLA pathology professor and senior researcher
DNA methylation reflects the health status of a tissue. It's a very informative signal.— Wenyuan Li, UCLA pathology professor
The Hearth Conversation Another angle on the story
Why does it matter that the test can identify where in the body the signal comes from?
Because a positive blood test without that information would send you scrambling. You'd need imaging of your liver, your lungs, your ovaries—everywhere. If the test can say "this signal is coming from your liver," your doctor knows exactly where to look next. It makes the follow-up efficient and focused.
The detection rate for early-stage cancers is 55 percent. That's less than half. How is that promising?
It's promising because it's better than nothing, and because early detection is the whole point. If you catch a cancer you would have missed otherwise, even at 55 percent sensitivity, you've changed that person's life. But you're right—it's not a replacement for other screening methods yet. It's another tool.
What's the background noise problem, exactly?
Most of the DNA in your blood comes from healthy cells dying naturally. That's 80 to 90 percent of what's floating around. If you're trying to spot the signal from a tumor or a diseased organ, you're looking for a whisper in a crowd. The filtering technique removes most of that crowd noise first.
So this test could replace colonoscopies or mammograms?
Not yet. Not based on this study. This is a screening tool that might flag something worth investigating further. The imaging and biopsies would still come after. But imagine if a simple blood draw could tell you which organ to focus on—that changes the whole screening process.
Why did liver cancer detection work so much better than other cancers?
The study doesn't say explicitly, but liver cancer cells probably shed DNA into the bloodstream in a way that creates a clearer methylation signature. Or the liver's position in the body makes its DNA more accessible in blood. That's a question for the next phase of research.